EBR Systems announced that it received commitments for a fully underwritten institutional placement to raise $36.1 million ...

The heart is arguably one of the most critical organs within the human body, pumping oxygen-rich blood throughout. While ...

Background: Many patients eligible for cardiac resynchronization therapy (CRT ... patients undergoing the new implantation of a CRT device between April 15, 2004 and August 6, 2007.

cardiac resynchronization therapy, or antitachycardia pacing) are important drawbacks. In summary, many advances have been made in drug, ablation, and device therapy for cardiac arrhythmias (Fig.

ASX health stocks have had a strong week with a wave of capital raisings in the sector as firms seek to strengthen their balance sheets.

A stretchable, flexible nanocomposite fiber offers a less invasive option for urgent cardiac care and severe arrhythmias.

Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR ...

Boston Scientific said on Wednesday it has discontinued sales of its heart device in the European Union and will not seek approval in the U.S. and other markets due to increased clinical and ...

The FDA gave the OK for the North Chicago-based medical device maker's Tendyne transcatheter mitral valve replacement.

Researchers found that peri-coronary adipose tissue attenuation (PCAT), a marker of coronary inflammation, is independently ...